361 related articles for article (PubMed ID: 20185343)
1. Effects of intra-articular administration of sodium hyaluronate on plasminogen activator system in temporomandibular joints with osteoarthritis.
Tang YL; Zhu GQ; Hu L; Zheng M; Zhang JY; Shi ZD; Liang XH
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr; 109(4):541-7. PubMed ID: 20185343
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
3. [Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis].
Gotoh H; Yamada H; Yoshihara Y; Kikuchi T; Obata K; Shinmei M
Ryumachi; 1997 Feb; 37(1):3-8. PubMed ID: 9128417
[TBL] [Abstract][Full Text] [Related]
4. [Study on the effect of sodium hyaluronate intra-articular injection on the treatment of knee osteoarthritis].
Xu P; Zhang Y; Yao J
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2005 Mar; 19(3):210-4. PubMed ID: 15828478
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
6. [Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis].
Wang WC; Wang Y; Sun CJ
Hunan Yi Ke Da Xue Xue Bao; 2001 Jun; 26(3):257-60. PubMed ID: 12536699
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis.
Nonaka T; Kikuchi H; Ikeda T; Okamoto Y; Hamanishi C; Tanaka S
J Rheumatol; 2000 Apr; 27(4):997-1004. PubMed ID: 10782829
[TBL] [Abstract][Full Text] [Related]
8. A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate in synovial joints with osteoarthritis.
Foti C; Cisari C; Carda S; Giordan N; Rocco A; Frizziero A; Della Bella G
Eur J Phys Rehabil Med; 2011 Sep; 47(3):407-15. PubMed ID: 21946401
[TBL] [Abstract][Full Text] [Related]
9. Osteoarthritis of the temporomandibular joint: an evaluation of the effects and complications of corticosteroid injection compared with injection with sodium hyaluronate.
Bjørnland T; Gjaerum AA; Møystad A
J Oral Rehabil; 2007 Aug; 34(8):583-9. PubMed ID: 17650168
[TBL] [Abstract][Full Text] [Related]
10. [Randomized controlled trial of sodium hyaluronate for degenerative disorders of the temporomandibular joint].
Shi ZD; Yang F; Zhang JY; Shi B
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2002 Jan; 16(1):11-5. PubMed ID: 11826641
[TBL] [Abstract][Full Text] [Related]
11. Control of the chondrocyte fibrinolytic balance by the drug piroxicam: relevance to the osteoarthritic process.
Fibbi G; Serni U; Matucci A; Mannoni A; Pucci M; Anichini E; Del Rosso M
J Rheumatol; 1994 Dec; 21(12):2322-8. PubMed ID: 7699636
[TBL] [Abstract][Full Text] [Related]
12. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
Xiao W; Tong WL; Ma DD
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
[TBL] [Abstract][Full Text] [Related]
13. Conservative treatment of temporomandibular joint osteoarthrosis: intra-articular injection of sodium hyaluronate.
Guarda-Nardini L; Masiero S; Marioni G
J Oral Rehabil; 2005 Oct; 32(10):729-34. PubMed ID: 16159350
[TBL] [Abstract][Full Text] [Related]
14. Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Pelletier JP; McCollum R; Cloutier JM; Martel-Pelletier J
Br J Rheumatol; 1992; 31 Suppl 1():19-26. PubMed ID: 1555050
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
16. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
17. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
18. Oral Glucosamine Hydrochloride Combined With Hyaluronate Sodium Intra-Articular Injection for Temporomandibular Joint Osteoarthritis: A Double-Blind Randomized Controlled Trial.
Yang W; Liu W; Miao C; Sun H; Li L; Li C
J Oral Maxillofac Surg; 2018 Oct; 76(10):2066-2073. PubMed ID: 29864430
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
[TBL] [Abstract][Full Text] [Related]
20. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts.
Hilal G; Martel-Pelletier J; Pelletier JP; Duval N; Lajeunesse D
Arthritis Rheum; 1999 Oct; 42(10):2112-22. PubMed ID: 10524682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
